Abbott’s recurring-revenue medtech franchises and Exact Sciences expansion support a compelling five-year compounding case, tempered by infant-formula litigation and post-acquisition leverage.
Overview
Abbott is a diversified global healthcare company operating Medical Devices, Diagnostics, Nutritional Products, and Established Pharmaceuticals, with FY2025 net sales of $44.33 billion and customers in more than 160 countries. Its combination of recurring CGM sensors, diagnostic reagents, nutrition, and chronic-disease products supports resilient cash generation; Medical Devices generated $21.39 billion of FY2025 revenue. The strategic growth case centers on FreeStyle Libre, structural heart and electrophysiology, and the March 2026 acquisition of Exact Sciences, which added a $3.2 billion Cancer Diagnostics business. Q2 2026 sales were $12.593 billion, up 13.0% reported but 4.8% organically; adjusted EPS of $1.31 beat consensus, and adjusted gross margin expanded 100 basis points to 58.0%. Abbott raised FY2026 adjusted EPS guidance to $5.45–$5.60 and reaffirmed 6.5%–7.5% organic growth. At approximately $98.50, shares trade at 17.8x FY2026 consensus EPS of $5.52 versus a five-year average of 22.5x, reflecting post-deal debt and formula litigation concerns. **Libre adoption and Exact Sciences cross-selling are pivotal catalysts; litigation and leverage are the principal overhangs.**